SG11201702769QA - Improved peptide inhibitors of sodium channels - Google Patents

Improved peptide inhibitors of sodium channels

Info

Publication number
SG11201702769QA
SG11201702769QA SG11201702769QA SG11201702769QA SG11201702769QA SG 11201702769Q A SG11201702769Q A SG 11201702769QA SG 11201702769Q A SG11201702769Q A SG 11201702769QA SG 11201702769Q A SG11201702769Q A SG 11201702769QA SG 11201702769Q A SG11201702769Q A SG 11201702769QA
Authority
SG
Singapore
Prior art keywords
sodium channels
peptide inhibitors
improved peptide
improved
inhibitors
Prior art date
Application number
SG11201702769QA
Inventor
Robert Tarran
Dale J Christensen
Original Assignee
Univ North Carolina
Spyryx Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina, Spyryx Biosciences Inc filed Critical Univ North Carolina
Publication of SG11201702769QA publication Critical patent/SG11201702769QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG11201702769QA 2014-10-08 2015-10-08 Improved peptide inhibitors of sodium channels SG11201702769QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462061461P 2014-10-08 2014-10-08
PCT/US2015/054693 WO2016057795A1 (en) 2014-10-08 2015-10-08 Improved peptide inhibitors of sodium channels

Publications (1)

Publication Number Publication Date
SG11201702769QA true SG11201702769QA (en) 2017-05-30

Family

ID=55653774

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201702769QA SG11201702769QA (en) 2014-10-08 2015-10-08 Improved peptide inhibitors of sodium channels

Country Status (14)

Country Link
US (4) US20160102121A1 (en)
EP (1) EP3204029A4 (en)
JP (1) JP2017536334A (en)
KR (1) KR20170083530A (en)
CN (1) CN107206046A (en)
AU (1) AU2015330895A1 (en)
BR (1) BR112017007224A2 (en)
CA (1) CA2963142A1 (en)
IL (1) IL251016A0 (en)
MX (1) MX2017004653A (en)
PH (1) PH12017500613A1 (en)
RU (1) RU2017115994A (en)
SG (1) SG11201702769QA (en)
WO (1) WO2016057795A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200031866A1 (en) * 2016-09-29 2020-01-30 Spyryx Biosciences, Inc. Peptide inhibitors of sodium channels
CA3046361A1 (en) 2016-12-13 2018-06-21 Spyryx Biosciences, Inc. Saline formulations of splunc1 peptides
WO2019067887A1 (en) * 2017-09-29 2019-04-04 Spyryx Biosciences, Inc. Enac inhibitor peptides and uses thereof
CN115944711A (en) * 2021-12-28 2023-04-11 四川好医生攀西药业有限责任公司 Application of tetrapeptide in preparation of medicine for repairing mucosal injury or skin injury

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW432305B (en) * 1997-03-31 2001-05-01 Hitachi Ltd Electronic commerce transaction system
US7384910B2 (en) 1997-10-08 2008-06-10 Castillo Gerardo M Small peptides for the treatment of Alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders
US20050192221A1 (en) 2003-12-04 2005-09-01 Mccray Paul B.Jr. Methods and compositions related to plunc polypeptides
PT1809271E (en) * 2004-09-10 2010-08-30 Newron Pharm Spa Use of (r)-(halobenzyloxy) benzylamino-propanamides as sodium and/or calcium channel selective modulators
WO2006045710A2 (en) * 2004-10-27 2006-05-04 Novo Nordisk A/S Insulin receptor binding peptides with non-insulin gene activation profiles and uses thereof
US20080032943A1 (en) 2005-11-04 2008-02-07 Johji Inazawa Method for detecting cancer and a method for suppressing cancer
US7951781B2 (en) 2006-11-02 2011-05-31 University Of Iowa Research Foundation Methods and compositions related to PLUNC surfactant polypeptides
EP2231280B1 (en) * 2007-12-10 2016-08-10 Novartis AG Amiloride-like Pyrazine-carboxamides as ENaC blockers
US9549967B2 (en) 2009-05-29 2017-01-24 The University Of North Carolina At Chapel Hill Regulation of sodium channels by PLUNC proteins
US9018169B2 (en) 2011-03-18 2015-04-28 Duke University Peptides for suppressing inflammation
EP2760463B1 (en) * 2011-09-20 2018-11-21 The University of North Carolina At Chapel Hill Regulation of sodium channels by plunc proteins
US9567367B2 (en) * 2012-01-16 2017-02-14 Atox Bio Ltd. Synthetic peptides for treatment of bacterial infections

Also Published As

Publication number Publication date
US20190071468A1 (en) 2019-03-07
PH12017500613A1 (en) 2017-09-04
RU2017115994A (en) 2018-11-12
BR112017007224A2 (en) 2018-03-06
RU2017115994A3 (en) 2019-03-01
US9796768B2 (en) 2017-10-24
US10150796B2 (en) 2018-12-11
WO2016057795A1 (en) 2016-04-14
US20170226180A1 (en) 2017-08-10
US20170327538A1 (en) 2017-11-16
CN107206046A (en) 2017-09-26
MX2017004653A (en) 2017-10-16
US20160102121A1 (en) 2016-04-14
CA2963142A1 (en) 2016-04-14
AU2015330895A1 (en) 2017-03-30
EP3204029A1 (en) 2017-08-16
IL251016A0 (en) 2017-04-30
KR20170083530A (en) 2017-07-18
EP3204029A4 (en) 2018-07-11
JP2017536334A (en) 2017-12-07

Similar Documents

Publication Publication Date Title
IL288519A (en) Inhibitors of ret
IL287113A (en) Smyd inhibitors
IL251584A0 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
HK1245247A1 (en) Inhibitors of bromodomains
IL246902A0 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
ZA201700304B (en) Spirocycloheptanes as inhibitors of rock
IL250511A0 (en) Solid state forms of ibrutinib
ZA201604272B (en) Inhibitors of glutaminase
IL248895A0 (en) Phosphatidylinositol -kinase inhibitors
EP3183255C0 (en) Spiropyrrolidines as mdm2 inhibitors
GB201521059D0 (en) Inhibitors of metallo-beta-lactamases
PT3334734T (en) Form c of avibactam sodium
ZA201706282B (en) Solid forms of menaquinols
GB201501004D0 (en) Inhibitors
IL251016A0 (en) Improved peptide inhibitors of sodium channels
SG11201609739UA (en) Derivatives of dolaproine-dolaisoleuine peptides
GB201520949D0 (en) Inhibitors
GB201504211D0 (en) Use of peptides
GB201418154D0 (en) Inhibitors
GB201405156D0 (en) Theory of parliament